Capstone Holding Corp. lowers convertible note conversion price to $1.00
Paula Green, Senior Vice President of Human Resources at Twist Bioscience Corp (NASDAQ:TWST), a $1.56 billion biotechnology company whose stock has declined nearly 49% over the past six months, sold 1,255 shares of common stock on August 4, 2025, at a price of $28.364, for a total value of $35,596. According to InvestingPro analysis, the stock is currently trading near its 52-week low of $27.12. Following the transaction, Green directly owns 126,206 shares of Twist Bioscience.
In other recent news, Twist Bioscience Corporation reported a notable 18% increase in revenue for Q3 2025, reaching $96.1 million. Despite this growth, the company experienced an adjusted EBITDA loss of $8 million, which was an improvement compared to the previous fiscal year. In addition to financial developments, Twist Bioscience announced the appointment of Trynka Shineman Blake to its board of directors. Blake, who has an extensive background with Vistaprint, will also serve on the audit committee. On the analyst front, JPMorgan lowered its price target for Twist Bioscience to $25, maintaining an Underweight rating. Similarly, TD Cowen adjusted its price target to $36, citing changes in fiscal year 2025 guidance, but retained a Buy rating. Evercore ISI also revised its price target to $46, maintaining an Outperform rating, following strong performance in the next-generation sequencing segment. These adjustments reflect ongoing evaluations of Twist Bioscience’s market position and financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.